BioWorld

Oct. 1, 2009

New Cash in Hand, Threshold Plans Hypoxia Cancer Efforts

Threshold Pharmaceuticals Inc. plans to raise about $35 million through the sale of stock and warrants, money that will help advance its cancer drug pipeline and extend its cash well into 2011. (BioWorld Today) Read More

Dyax Prices 5.5M Shares Ahead of DX-88 Approval, Partnership

Epidemiology Fails to Confirm Link Between Strep, Tics, OCD

Expanded Access Programs Vital, but New Rules Raise Concerns

Other News To Note

Clinic Roundup

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for June 12, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 9, 2026

Pre-disease plasma signature may help redefine lung cancer risk

BioWorld

Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...

New 5-HT2C receptor agonists reported in Hansoh patent

BioWorld Science

Researchers from Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have disclosed tricyclic compounds acting as 5-HT2C receptor...

Virtual IPO word with stock graph and arrow

Parabilis takes top spot, pricing largest biopharma IPO at $670M

BioWorld

Less than two months after Kailera Therapeutics Inc. made headlines with biopharma’s largest IPO to date, Parabilis Medicines Inc. has come along and surpassed...